Phase 3 primary completion: Efficacy and safety of Deucravacitinib in adults with active Sjögren's Syndrome.
FDA catalyst calendar
Confirmed PDUFA dates, advisory committees and Phase 3 readouts. Every entry links to its primary source.
1 events · Clear filters
November 2026 1
- Nov2026
Bristol-Myers Squibb — Deucravacitinib